{
    "nct_id": "NCT06625047",
    "official_title": "Neuro-Oncology Anywhere 242: Pilot Study Evaluating Telehealth and In-Person Assessments in Patients With Glioma Receiving Oral Chemotherapy",
    "inclusion_criteria": "* Age ≥ 18 years\n* Diagnosis of glioma requiring adjuvant chemotherapy. Patients with glioblastoma (GBM); astrocytoma, IDH-mutant; oligodendroglioma IDH-mutant, 1p/19q codeleted are eligible\n* Patients eligible to receive temozolomide as standard of care adjuvant therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60\n* Expected survival ≥ 6 months in the opinion of treatment team\n* Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations\n* Participants who do not have devices that will permit telehealth visits will be provided such tablet devices to facilitate appointments for the duration of the study\n* Participants who do not have financial resources to travel for in-person visits will be provided assistance for cost of travel\n* Ability to complete patient experience surveys by the participant with or without assistance from their caregiver\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings\n* Pregnant or nursing, imprisoned, or lacking capacity for understanding\n* Unable to swallow tablets or at risk for impaired absorption of oral medication\n* Known hypersensitivity or allergy to temozolomide",
    "miscellaneous_criteria": ""
}